UA-30 mitigates systemic aging and motor decline by inhibiting RalA signaling in naturally aged mice.

UA-30 delays systemic aging and improves muscle function in naturally aged mice by inhibiting RalA signaling, reducing fibrosis, and extending lifespan.

• Why it matters: Aging leads to physiological decline and diseases like sarcopenia, with limited effective therapies, highlighting the need for novel interventions targeting underlying mechanisms.
• What they did: Researchers developed UA-30, a compound with good safety and pharmacokinetics, and treated aged mice to assess its effects on aging markers, muscle health, and molecular pathways, including identifying RalA as a target.
• The result: UA-30 reduced fibrosis and muscle atrophy, slowed epigenetic aging, extended lifespan, and improved muscle function, demonstrating its potential as a therapeutic for age-related muscle degeneration by targeting RalA.